Proactiveinvestors recommends

Additional Information

Market:	ASX
Sector:	Medical Equipment
EPIC:	SOM
Latest Price:	0.97 (0.00%)
52-week High:	1.49
52-week Low:	0.91
Market Cap:	39.70M

1 year chart

1 day chart

SomnoMed

SomnoMed Limited (ASX: SOM) specialises in products for sleep apnea and anti-snoring through its patented mandibular advancement splint, the SomnoDent MAS. The company's SomnoDent® MAS devices and services are provided to Patients, Dentists and Sleep Specialists.

SomnoMed showcases SomnoDent sleep apnea device at SLEEP 2009

Wednesday, June 17, 2009

Showcasing its SomnoDent™ MAS dental sleep apnea device, SomnoMed (ASX: SOM) has participated at the Annual SLEEP 2009 exhibition in Seattle. This is the centre point for Dental Sleep Medicine and the Sleep Medicine fraternity worldwide.

SomnoDent™ MAS was featured for a record number of American Association of Dental Sleep Medicine (AADSM) practitioners, with over 600 delegates and the medical conference of Associated Professional Sleep Societies (APSS), which attracted more than 6,000 delegates.

Exhibition activities were focused on the positioning of the SomnoDent MAS therapy as a patented, clinically proven and compliant third generation OSA treatment option for sleep disordered breathing.

The SomnoDent™ MAS dental sleep device consists of two acrylic plates fitted over the upper and low teeth. A patented fin coupling mechanism on the lower arch accurately positions the lower jaw (mandible) a little forward of its natural position.

Ralf Barschow, SomnoMed's CEO said that SLEEP 2009 was a very important strategic investment for SomnoMed and "I am very pleased with the response. It offered an ideal opportunity to present the SomnoDent™ MAS therapeutic option to a broader medical fraternity."

SomnoMed is positioning the SomnoDent™ MAS therapy as a patented, clinically proven and compliant third generation OSA treatment option for sleep disordered breathing.

Barschow said SLEEP 2009 "also confirmed our view that there is a significant demand for the SomnoDent MAS therapy for all patients diagnosed and untreated, as well as non-compliant to traditional treatment options, such as surgery or CPAP."

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.